An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

被引:12
作者
Jilani, Iman [1 ]
Kantarjian, Hagop [2 ]
Faraji, Homan [1 ]
Gorre, Mercedes [1 ]
Cortes, Jorge [2 ]
Ottmann, Oliver [3 ]
Bhalla, Kapil [4 ]
O'Brien, Susan [2 ]
Giles, Francis [2 ]
Albitar, Maher [1 ]
机构
[1] Quest Diagnost Nichols Inst, Dept Hematol, San Juan Capistrano, CA 92690 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Goethe Univ Frankfurt, Dept Leukemia, Frankfurt, Germany
[4] HL Moffitt Canc Ctr, Dept Leukemia, Tampa, FL 33612 USA
关键词
BCR-ABL; fusion protein; CML; beads; phosphorylation; MDR; imatinib;
D O I
10.1016/j.leukres.2007.11.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have developed a simplified sandwich immunoassay to measure free circulating total and phosphorylated fusion BCR-ABL protein in patients with the t(9;22)(q34;q11) chromosomal translocation. The assay is based on immunoprecipitating BCR-ABL protein using beads coated with anti-BCR antibody and detecting the fusion protein with anti-ABL antibody and flow cytometry. We show that this method allows the quantification of this protein in the plasma and may allow the measurement of tumor load. This method also allows the measurement of the level of phosphorylation of the immunoprecipitated BCR-ABL using antibodies against phosphorylated ABL protein, which can be used for monitoring of therapy with kinase inhibitors. The sensitivity of this immunoassay was comparable to the sensitivity of reverse transcription-polymerase chain reaction (RT-PCR) assay. This technique is useful in monitoring patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), but the same approach can be used in other translocations and has the potential of multiplexing. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:936 / 943
页数:8
相关论文
共 16 条
  • [1] Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
    Albitar, M
    Do, KA
    Johnson, MM
    Giles, FJ
    Jilani, I
    O'Brien, S
    Cortes, J
    Thomas, D
    Rassenti, LZ
    Kipps, TJ
    Kantarjian, HM
    Keating, M
    [J]. CANCER, 2004, 101 (05) : 999 - 1008
  • [2] c-Ab1 has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines
    Brasher, BB
    Van Etten, RA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (45) : 35631 - 35637
  • [3] Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
    Cortes, J
    Giles, F
    O'Brien, S
    Thomas, D
    Albitar, M
    Rios, MB
    Talpaz, M
    Garcia-Manero, G
    Faderl, S
    Letvak, L
    Salvado, A
    Kantarjian, H
    [J]. CANCER, 2003, 97 (11) : 2760 - 2766
  • [4] The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    Deininger, M
    Buchdunger, E
    Druker, BJ
    [J]. BLOOD, 2005, 105 (07) : 2640 - 2653
  • [5] Imatinib therapy in chronic myelogenous leukemia:: strategies to avoid and overcome resistance
    Hochhaus, A
    La Rosée, P
    [J]. LEUKEMIA, 2004, 18 (08) : 1321 - 1331
  • [6] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Gambacorti-Passerini, C
    Niederwieser, D
    Resta, D
    Capdeville, R
    Zoellner, U
    Talpaz, M
    Druker, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) : 645 - 652
  • [7] Kantarjian HM, 2003, CLIN CANCER RES, V9, P160
  • [8] Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia
    Ma, Wanlong
    Tseng, Richard
    Gorre, Mercedes
    Jilani, Iman
    Keating, Michael
    Kantarjian, Hagop
    Cortes, Jorge
    O'Brien, Susan
    Giles, Francis
    Albitar, Maher
    [J]. HAEMATOLOGICA, 2007, 92 (02) : 170 - 175
  • [9] Phosphatidylinositol-3 kinase inhibitors reproduce the selective anti proliferative effects of imatinib on chronic myeloid leukaemia progenitor cells
    Marley, SB
    Lewis, JL
    Schneider, H
    Rudd, CE
    Gordon, MY
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (04) : 500 - 511
  • [10] Martinelli G, 2005, HAEMATOLOGICA, V90, P534